Correlation Between HCW Biologics and Lumos Pharma
Can any of the company-specific risk be diversified away by investing in both HCW Biologics and Lumos Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining HCW Biologics and Lumos Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between HCW Biologics and Lumos Pharma, you can compare the effects of market volatilities on HCW Biologics and Lumos Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in HCW Biologics with a short position of Lumos Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of HCW Biologics and Lumos Pharma.
Diversification Opportunities for HCW Biologics and Lumos Pharma
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between HCW and Lumos is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding HCW Biologics and Lumos Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lumos Pharma and HCW Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on HCW Biologics are associated (or correlated) with Lumos Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lumos Pharma has no effect on the direction of HCW Biologics i.e., HCW Biologics and Lumos Pharma go up and down completely randomly.
Pair Corralation between HCW Biologics and Lumos Pharma
If you would invest 43.00 in HCW Biologics on December 28, 2024 and sell it today you would lose (13.00) from holding HCW Biologics or give up 30.23% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 0.0% |
Values | Daily Returns |
HCW Biologics vs. Lumos Pharma
Performance |
Timeline |
HCW Biologics |
Lumos Pharma |
Risk-Adjusted Performance
Very Weak
Weak | Strong |
HCW Biologics and Lumos Pharma Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with HCW Biologics and Lumos Pharma
The main advantage of trading using opposite HCW Biologics and Lumos Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if HCW Biologics position performs unexpectedly, Lumos Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lumos Pharma will offset losses from the drop in Lumos Pharma's long position.HCW Biologics vs. Day One Biopharmaceuticals | HCW Biologics vs. Mirum Pharmaceuticals | HCW Biologics vs. Rocket Pharmaceuticals | HCW Biologics vs. Avidity Biosciences |
Lumos Pharma vs. Shattuck Labs | Lumos Pharma vs. Champions Oncology | Lumos Pharma vs. Century Therapeutics | Lumos Pharma vs. Silo Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Complementary Tools
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Fundamental Analysis View fundamental data based on most recent published financial statements |